#151215

Anti-ErbB4 [HFR1]

Cat. #151215

Anti-ErbB4 [HFR1]

Cat. #: 151215

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: ErbB4 (Her4, p180erbB4)

Class: Monoclonal

Application: FACS ; IHC ; IF ; IP ; WB

Reactivity: Human ; Mouse

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Bill Gullick

Institute: Imperial Cancer Research Fund

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-ErbB4 [HFR1]
  • Research fields: Cancer;Cell biology;Cell signaling and signal transduction
  • Clone: HFR1
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human ; Mouse
  • Host: Mouse
  • Application: FACS ; IHC ; IF ; IP ; WB
  • Description: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB4 is involved in cell growth regulation and its expression or function may be altered in human cancers.
  • Immunogen: Synthetic peptide sequence RSTLQHPDYLQEYST from the cytoplasmic domain of the protein (residues 1249-1264.)
  • Isotype: IgG2b
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: ErbB4 (Her4, p180erbB4)
  • Target background: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB4 is involved in cell growth regulation and its expression or function may be altered in human cancers.

Applications

  • Application: FACS ; IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
  • Ko et al. 2010. Breast Cancer Res. 12(6):R100. PMID: 21092257.
  • Gulati et al. 2010. Diagn Pathol. 5:18. PMID: 20331873.
  • Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.
  • Sundvall et al. 2007. Oncogene. 26(48):6905-14. PMID: 17486069.
  • Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains.
  • Carn et al. 2005. Mol Cancer Ther. 4(2):243-55. PMID: 15713896.
  • H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
  • Srinivasan et al. 1998. J Pathol. 185(3):236-45. PMID: 9771476.
  • Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types.